Researchers Report a Novel Imaging Tool to Assess Prostate Cancer Recurrence

Researchers Report a Novel Imaging Tool to Assess Prostate Cancer Recurrence
A study recently published in The Journal of Nuclear Medicine revealed a new tool based on imaging to assess prostate cancer recurrence in patients after radical prostatectomy. The study was led by researchers at the Technische Universität München in Germany and is entitled “Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy.” Prostate cancer is the second most common cancer in men, with almost one million new cases diagnosed every year worldwide. It is estimated that one in every seven men will be diagnosed with this cancer during their lifetimes. It is a curable cancer that can range from slow-growing tumors (more common) to rapidly progressing aggressive tumors, which are more difficult to treat. Early detection and treatment of prostate cancer is therefore crucial. The diagnosis can be made through a blood test for prostate-specific antigens (PSA, a protein produced by prostate cells). One of the treatment options for prostate cancer is radical prostatectomy, where the prostate gland and some of the surrounding tissue is surgically removed. However, a considerable number of patients who undergo prostatectomy later experience an increase in PSA levels, representing a biochemical recurrence linked to higher risk for cancer recurrence. It is known that prostate-specific membrane antigen (PSMA) expression is increased in prostate cancer cells. A ligand of PSMA was recently developed, named 68G
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *